Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors

NCT00724100 is registered in ClinicalTrials.gov with Albany Molecular Research, Inc. as lead sponsor.

NCT NCT00724100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00724100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors
Lead sponsor
Albany Molecular Research, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2008
Completion date
December 31, 2010
Enrollment
46 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer